Iterum Therapeutics Plc (ITRM) –
-
Form 8-K Iterum Therapeutics plc For: Apr 03
-
Form 8-K Iterum Therapeutics plc For: Mar 28
-
Form 10-K Iterum Therapeutics plc For: Dec 31
-
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
-
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
-
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
-
Form 8-K Iterum Therapeutics plc For: Mar 06
-
Iterum Therapeutics Plc (ITRM) Provides Business Update
-
Iterum Therapeutics Provides Business Update
-
H.C. Wainwright Upgrades Iterum Therapeutics (ITRM) to Buy
-
Form SC 13G Iterum Therapeutics plc Filed by: Point72 Asset Management, L.P.
-
Form 8-K Iterum Therapeutics plc For: Jan 30
-
Form 8-K Iterum Therapeutics plc For: Jan 30
-
Iterum Therapeutics (ITRM) Reports Positive Topline Results from its Phase 3 REASSURE Trial of Oral Sulopenem
-
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
-
Maxim Group Starts Iterum Therapeutics (ITRM) at Buy
-
Iterum Therapeutics Plc (ITRM) Announces Resignation of Mark Chin from Board
-
Form 8-K Iterum Therapeutics plc For: Dec 28
-
Form 4 Iterum Therapeutics plc For: Dec 22 Filed by: Dunne Michael W.
-
Form 4 Iterum Therapeutics plc For: Dec 18 Filed by: Dunne Michael W.
-
Form DEFA14A Iterum Therapeutics plc
-
Form DEF 14A Iterum Therapeutics plc For: Jan 30
-
Form PRE 14A Iterum Therapeutics plc For: Jan 30
-
Form 4 Iterum Therapeutics plc For: Dec 01 Filed by: Puttagunta Sailaja
-
Form 8-K Iterum Therapeutics plc For: Dec 04
-
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
-
Form 4 Iterum Therapeutics plc For: Nov 22 Filed by: Dunne Michael W.
-
Form 4 Iterum Therapeutics plc For: Nov 20 Filed by: Fishman Corey N.
-
Form 10-Q Iterum Therapeutics plc For: Sep 30
-
Form 8-K Iterum Therapeutics plc For: Nov 14
-
Iterum Therapeutics Plc (ITRM) Tops Q3 EPS by 58c
-
Iterum Therapeutics Reports Third Quarter 2023 Financial Results
-
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023
-
Form 8-K Iterum Therapeutics plc For: Oct 24
-
Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
-
Iterum Therapeutics to Present Data at IDWeek 2023
-
Form 4 Iterum Therapeutics plc For: Oct 01 Filed by: HUNT RONALD
-
Form 4 Iterum Therapeutics plc For: Oct 01 Filed by: Dunne Michael W.
-
Form 8-K Iterum Therapeutics plc For: Sep 26
-
Form 10-Q Iterum Therapeutics plc For: Jun 30
-
Form 8-K Iterum Therapeutics plc For: Aug 11
-
Iterum Therapeutics Plc (ITRM) Misses Q2 EPS by 23c
-
Iterum Therapeutics Reports Second Quarter 2023 Financial Results
-
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023
-
Form 8-K Iterum Therapeutics plc For: Aug 01
-
Form DEFA14A Iterum Therapeutics plc
-
Form DEFA14A Iterum Therapeutics plc
-
Form DEFA14A Iterum Therapeutics plc
-
Form 4 Iterum Therapeutics plc For: Jul 01 Filed by: HUNT RONALD
-
Form 4 Iterum Therapeutics plc For: Jul 01 Filed by: Dunne Michael W.
Back to ITRM Stock Lookup